Programme: Breast Cancer Europe Roundtable 2019

Wednesday 23rd May, Brussels

Chair: Prof. Robert Mansel CBE

Emeritus Professor of Surgery, Cardiff University School of Medicine, UK

09:30 - 10:00 Registration and Morning Coffee
10:00 — 11:45

Session I: Analysing the Current Policy Framework of Non-metastatic and Metastatic Breast Cancer in the EU and Member States

  • Introduction & opening of roundtable
  • Viewpoint: Updates from the European Commission Initiative on Breast Cancer by Dr. Luciana Neamtiu, Project Officer, European Initiative on Breast Cancer (ECICC), JRC – European
    Commission
  • Viewpoint: Lieve Wierinck MEP, Member MAC Group, European Parliament
  • Viewpoint: Mona Knotek-Roggenbauer, President Europa Donna - The European Breast Cancer Coalition
  • Improving EU-wide collaboration between cancer registries, training and disseminating information on incidence and mortality: What steps need to be taken?
  • Pan-European equity in cancer treatment: where are we?
11:45 — 12:00 Coffee Break
12:00 — 13:00 Session II: Improving Early Prevention, Diagnosis and Patient Treatment
  • Early detection & accurate screening and rapid diagnosis practices
  • Best practices: Overcoming participation barriers in breast cancer screening
  • Novel strategies on Personalized Medicines for treatment and patient care
  • Therapy options; the role of immunotherapy, chemotherapy, surgery, hormone therapy and radiotherapy
  • How can we ensure the provision of a consistent treatment strategy across a multi-disciplinary team (MDT)?
  • Updates from Clinical Trials: Katherine Phase III, TAM-01 Phase III and GEICAM/CIBOMA Phase III
13:00 — 14:00 Networking Lunch
14:00 — 15:15 Session III: Fostering Research, Innovation and Drugs Development
  • Metastatic Breast Cancer: Highlights and breakthroughs of 2018
  • Triple negative breast cancers (TNBCs): Clinical Trials & design of improved therapeutic strategies
  • Development of next-generation chemotherapeutic agents
  • How can we ensure flexibility in regulatory pathways and sustainable funding mechanisms to encourage R&D?
  • BRCA gene-mutant breast cancers: new therapeutics and approved treatments
15:15 — 15:45 Recommendations and Close of Roundtable
 
  • Recommendations for policy makers, governments and key stakeholders to support an EU-wide strategy : tour de table of each participant’s final recommendation for the Breast Cancer Report
  • Chair’s closing remarks